about
A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer.Thoughts on Jim Flaherty. When should physicians retire?Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Is there a role for oral or intravenous ascorbate (vitamin C) in treating patients with cancer? A systematic review.Publishing clinical research: ten pearls for oncology trainees and junior oncologists.Management of urogenital atrophy in breast cancer patients: a systematic review of available evidence from randomized trials.Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meetingLost in transition? Thoughts on retirement--"will you still need me, will you still feed me, when i'm sixty-four?".Definition and consequences of locally advanced breast cancer.Pharmacotherapy of bone metastases in breast cancer patients--an update.Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits.Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review.Treatment choices for patients with invasive lobular breast cancer: a doctor survey.Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients.Defining optimal control of chemotherapy-induced nausea and vomiting-based on patients' experience.Third-party online surveys-science, selling, or sugging?Surviving SurveysTreatment for locally advanced breast cancer
P50
Q30248333-3D97C8B1-82D6-4421-ABCB-027104F9F6C1Q33982683-AAB0CE86-432E-45FE-B991-4EBFC536E849Q34362184-C783D552-7B76-4C14-894A-7883146F14C8Q34458788-A2CA3838-CD52-473F-B487-E47795617E0BQ35072451-9DD71BE8-C956-4026-A0DC-36D79A21DBD3Q35640048-CCE4915D-4F23-49A6-A6AD-A50CCF1245FFQ36207662-2F9A99CD-A964-4A63-A3CE-3F52CA8B3DB2Q37301490-48376E2C-AF33-45FA-B127-2115C705A8E1Q38165730-6DAF2833-BECC-48C3-9A14-66CDF192F419Q38199759-095424E6-C7D8-4440-909C-F85BC4722BE9Q38239754-99EC21B7-8341-4464-8ECA-0674298AA121Q38589647-772E5C05-B6C4-44D5-8A97-2581620BCC12Q38997433-885C280E-7894-49F2-AC3D-D3302EB07E86Q40987023-02BAD255-3ABB-4763-9B25-411B9F0443C2Q41644259-86B512B9-3BB6-45ED-BFAA-E3FF6973F289Q41657758-A8C5294A-E6E6-4EA9-9095-4EB0B161DD3FQ57301746-927DE310-DE8F-40B9-BFD0-5974B240E5DAQ62831161-629E99DE-BC18-4CCF-A3E5-4EB4EC61A79C
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carmel Jacobs
@ast
Carmel Jacobs
@en
Carmel Jacobs
@es
Carmel Jacobs
@nl
Carmel Jacobs
@sl
type
label
Carmel Jacobs
@ast
Carmel Jacobs
@en
Carmel Jacobs
@es
Carmel Jacobs
@nl
Carmel Jacobs
@sl
prefLabel
Carmel Jacobs
@ast
Carmel Jacobs
@en
Carmel Jacobs
@es
Carmel Jacobs
@nl
Carmel Jacobs
@sl
P106
P1153
55926102100
P21
P31
P496
0000-0001-5178-7307